Merck, Roche, AstraZeneca Dominate Lung Cancer Therapeutics:...

bir ses eklendi Histoire

2025-11-12 06:16:00

Merck, Roche, AstraZeneca Dominate Lung Cancer Therapeutics: Biosimilars and Niche Innovators Challenge $65B Market by 2030

The Lung Cancer Therapeutics Market, valued at $35 billion in 2023 and projected to reach $65 billion by 2030, is dominated by pharmaceutical giants Merck, Roche, and AstraZeneca. These firms leverage proprietary pipelines, global distribution, and strong clinician trust to maintain leadership, but emerging biotechs and biosimilars are eroding their monopoly, particularly in underserved...

0 Yorumlar 0 hisse senetleri 69 Views 0 önizleme